… However, less is known about these risk factors and AT or VTD episodes in patients with
antiphospholipid syndrome (APS). Our aim was to elucidate whether APS-related thrombotic …

… However, DOACs are not indicated in the treatment of patients with triple-positive
antiphospholipid syndrome (APS). This limitation is often extended in clinical practice to patients with …

… list all features that, in their experience, occur as part of the aPL/… encouraged to consider
their real-life experience with aPL-… /II methodology of the new antiphospholipid syndrome (APS) …

… patients with thrombotic antiphospholipid syndrome. This is a … Rivaroxaban, 20 mg once
daily (15 mg once daily based on … death in patients with antiphospholipid syndrome. Only high-…

… , and there is experience showing that only trace amounts of eculizumab passes the placenta
[30]. … Comparison of real world and core laboratory lupus anticoagulant results from the …

SIR, APS is an acquired autoimmune disorder characterized by the association of vascular
thrombosis … A few days after the switch, he experienced dyspnoea leading to the diagnosis of …

… Based on our retrospective experience with eight patients, there was no recurrence in three
patients who were warfarin-naïve (never received warfarin) after 7 patient years, and there …

Background: Antiphospholipid Syndrome (APS) is a disorder … Catastrophic Antiphospholipid
Syndrome (CAPS) is a very … of the presence of antiphospholipid antibodies, usually in high …

… In our experience, we recommend a primary thrombotic prophylaxis with LDA in patients
with a high-risk antibody profile (triple positivity, high titer), especially in the presence of …

… However, when patients present with multiple organ thromboses in a “real-world” setting, …
A minority of CAPS patients only experience the large vessel type occlusions typically seen …